Phenosense Combination HIV Drug Resistance Assay
Use
This test is useful for determining viral phenotype and genotype resistance to three classes of commonly prescribed antiretroviral drugs: nucleoside reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI). It also assesses viral replication capacity, providing comprehensive insights into HIV drug resistance.
Special Instructions
This test is intended for use only for patients with documented HIV-1 infection and viral loads greater than or equal to 500 copies/mL. For optimal results, viral loads should be confirmed within two weeks prior to submission for testing. Separate frozen specimens are recommended if multiple tests are requested, to avoid delays in turnaround time.
Limitations
The test may not be informative for patients with a viral load of less than 500 copies/mL. Samples collected from the same patient less than 30 days apart will be considered duplicates and canceled. Proper sample handling is crucial; samples that are not centrifuged or those exposed to repeated freeze/thaw cycles may be rejected.
New York Approved
Methodology
Other
Biomarkers
Result Turnaround Time
18-26 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender-top (EDTA) or plasma preparation tube (PPT)
Collection Instructions
Draw blood in either PPT (pearl top) or lavender-top (EDTA) tubes. Centrifuge specimen within six hours of collection. Remove plasma from cells immediately, and transfer specimen to a screw-capped, plastic vial. Freeze 3 mL of PPT plasma or EDTA plasma immediately, send specimen frozen.
Causes for Rejection
PPT(TM) not centrifuged; quantity not sufficient for analysis; heparinized plasma; nonfrozen specimen; specimen exposed to repeated freeze/thaw cycles; specimen received in 'pop-top' or 'snap-cap' tube
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |